Annual report pursuant to Section 13 and 15(d)

INCOME TAXES (Details)

v3.10.0.1
INCOME TAXES (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Deferred tax assets      
Net operating loss carryforwards $ 226,388 $ 212,153  
Orphan drug and research and development credits 55,276 51,744  
Deferred compensation 7,155 12,261  
Capitalized research and development expenses 424 4,690  
Other, net 809 815  
Total deferred tax assets 290,052 281,663  
Valuation allowance $ (290,052) $ (281,663)  
Reconciliation of the statutory federal income tax rate to the effective tax rate      
Federal statutory tax rate (as a percent) (21.00%) (34.00%) (34.00%)
Federal statutory rate reduction   160.20%  
Valuation allowance (as a percent) 16.30% (126.50%) 35.00%
Stock compensation (as a percent) 8.20% 5.70% 5.00%
Orphan drug and research and development credits (3.70%) (3.60%) (7.30%)
Other, net (as a percent) 0.20% (1.80%) 1.30%
Effective tax rate (as a percent) 0.00% 0.00% 0.00%
Maximum      
Reconciliation of the statutory federal income tax rate to the effective tax rate      
Federal statutory tax rate (as a percent)   (35.00%)